Profile data is unavailable for this security.
About the company
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
- Revenue in USD (TTM)25.91m
- Net income in USD-254.87m
- Incorporated2007
- Employees38.00
- LocationCartesian Therapeutics Inc65 Grove StreetWATERTOWN 02472United StatesUSA
- Phone+1 (617) 923-1400
- Fax+1 (617) 924-3454
- Websitehttps://www.cartesiantherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | RNAC:NMQ since announced | Transaction value |
|---|---|---|
| Cartesian Therapeutics Inc | -11.38% | 6.81m |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | 61.51m | -44.77m | 436.73m | 99.00 | -- | 2.13 | -- | 7.10 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Ocugen Inc | 7.05m | -58.50m | 442.60m | 65.00 | -- | 14.63 | -- | 62.78 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 447.60m | 130.00 | -- | 0.6938 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 450.92m | 240.00 | -- | -- | -- | 1.96 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Annexon Inc | 0.00 | -120.74m | 450.97m | 70.00 | -- | 1.68 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 451.47m | 162.00 | -- | 1.32 | 297.41 | 3.79 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 453.09m | 38.00 | -- | -- | -- | 17.49 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| PepGen Inc | 0.00 | -80.33m | 455.79m | 64.00 | -- | 2.54 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Korro Bio Inc | 0.00 | -81.19m | 465.50m | 94.00 | -- | 2.66 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Lenz Therapeutics Inc | 0.00 | -117.37m | 470.09m | 6.00 | -- | 2.37 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Verve Therapeutics Inc | 16.05m | -196.83m | 470.21m | 255.00 | -- | 0.805 | -- | 29.30 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 470.48m | 127.00 | -- | 5.93 | -- | 94.10 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| Applied Therapeutics Inc | -477.00k | -193.56m | 477.64m | 26.00 | -- | 7.10 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 479.20m | 76.00 | -- | 2.24 | -- | 190.92 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 480.47m | 19.00 | -- | 4.87 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Cartesian Therapeutics Inc's reporting currency: US Dollar USD
8.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 478.96k | 2.69% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 304.55k | 1.71% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 220.93k | 1.24% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 206.02k | 1.16% |
| Geode Capital Management LLCas of 31 Mar 2024 | 83.30k | 0.47% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 69.56k | 0.39% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Mar 2024 | 45.88k | 0.26% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 39.33k | 0.22% |
| Millennium Management LLCas of 31 Mar 2024 | 33.15k | 0.19% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 31.18k | 0.18% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
